Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 19

1.

Progress against solid tumors in danger: the metastatic breast cancer example.

Cortés J, Calvo E, González-Martín A, Dawood S, Llombart-Cussac A, De Mattos-Arruda L, Gómez P, Silva O, Perez EA, Rugo HS, Lluch A, Hortobagyi GN.

J Clin Oncol. 2012 Oct 1;30(28):3444-7. Epub 2012 Aug 27. No abstract available.

PMID:
22927522
2.

Making genuine progress against metastatic breast cancer.

Lyman GH, Burstein HJ, Buzdar AU, D'Agostino R, Ellis PA.

J Clin Oncol. 2012 Oct 1;30(28):3448-51. Epub 2012 Aug 27. Review. No abstract available.

PMID:
22927527
3.

US Food and Drug Administration approval overview in metastatic breast cancer.

Cortazar P, Justice R, Johnson J, Sridhara R, Keegan P, Pazdur R.

J Clin Oncol. 2012 May 10;30(14):1705-11. doi: 10.1200/JCO.2011.39.2613. Epub 2012 Mar 19. Review. No abstract available.

4.

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

Valachis A, Polyzos NP, Patsopoulos NA, Georgoulias V, Mavroudis D, Mauri D.

Breast Cancer Res Treat. 2010 Jul;122(1):1-7. doi: 10.1007/s10549-009-0727-0. Epub 2010 Jan 9. Review.

PMID:
20063120
5.

What is the best choice of partner chemotherapy with trastuzumab for metastatic breast cancer?

Gourmelon C, Frenel JS, Campone M.

Expert Rev Anticancer Ther. 2012 Feb;12(2):195-201. doi: 10.1586/era.11.167. Review.

PMID:
22316367
6.

Bevacizumab for advanced breast cancer.

Traina TA, Rugo HS, Dickler M.

Hematol Oncol Clin North Am. 2007 Apr;21(2):303-19. Review.

PMID:
17512451
7.

[Avastin in the treatment of breast cancer].

Petráková K.

Klin Onkol. 2011;24(2):101-5. Review. Czech.

PMID:
21644364
8.

Approved agents for metastatic breast cancer.

Fornier MN.

Semin Oncol. 2011 Jun;38 Suppl 2:S3-10. doi: 10.1053/j.seminoncol.2011.04.003. Review.

PMID:
21600382
9.

The role of antiangiogenetic agents in the treatment of breast cancer.

Bareschino MA, Schettino C, Colantuoni G, Rossi E, Rossi A, Maione P, Ciardiello F, Gridelli C.

Curr Med Chem. 2011;18(33):5022-32. Review.

PMID:
22050750
10.

[Trastuzumab, a new treatment approach in breast carcinoma].

Raab G, Eiermann W.

Internist (Berl). 2001 Jun;42(6):835-40, 842. Review. German. No abstract available.

PMID:
11449630
11.

Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.

Schmucker C, Antes G, Lelgemann M.

Surv Ophthalmol. 2009 Nov-Dec;54(6):705-7. doi: 10.1016/j.survophthal.2009.08.002. Review. No abstract available.

PMID:
19818262
12.

Bevacizumab for the first-line treatment of human epidermal growth factor receptor 2-negative advanced breast cancer.

Damasceno M.

Curr Opin Oncol. 2011 Apr;23 Suppl:S3-9. doi: 10.1097/01.cco.0000397417.75245.9c. Review.

PMID:
21490481
13.

Bevacizumab in colorectal cancer: current and future directions.

Yeung Y, Tebbutt NC.

Expert Rev Anticancer Ther. 2012 Oct;12(10):1263-73. doi: 10.1586/era.12.104. Epub 2012 Oct 31. Review.

PMID:
23113577
14.

Targeting adjuvant chemotherapy: a good idea that needs to be proven!

Hayes DF.

J Clin Oncol. 2012 Apr 20;30(12):1264-7. doi: 10.1200/JCO.2011.38.4529. Epub 2012 Feb 21. Review. No abstract available.

PMID:
22355050
15.

[Metastatic breast cancer--new methods of treatment].

Rack B, Heinemann V, Schindlbeck C, Walther J, Salat C, Sommer H.

MMW Fortschr Med. 2008 Jan 17;150(1-2):34-6. Review. German. No abstract available.

PMID:
18300641
16.

The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: where does it fit?

Eskens FA, Sleijfer S.

Eur J Cancer. 2008 Nov;44(16):2350-6. doi: 10.1016/j.ejca.2008.07.042. Epub 2008 Sep 11. Review.

PMID:
18789679
17.

Patients with anti-HER2 responsive disease: definition and adjuvant therapies.

Burstein HJ.

Breast. 2011 Oct;20 Suppl 3:S132-4. doi: 10.1016/S0960-9776(11)70310-1. Review.

PMID:
22015280
18.

Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.

Miles D, Zielinski C, Martin M, Vrdoljak E, Robert N.

Eur J Cancer. 2012 Mar;48(4):482-91. doi: 10.1016/j.ejca.2011.12.007. Epub 2012 Jan 16. Review.

PMID:
22257791
19.

Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension.

Nazer B, Humphreys BD, Moslehi J.

Circulation. 2011 Oct 11;124(15):1687-91. doi: 10.1161/CIRCULATIONAHA.110.992230. Review. No abstract available.

Supplemental Content

Support Center